Novel pharmaceutical strategies targeting the gut microbiota

Implexion develops pharmaceutical strategies to inhibit microbial production of harmful substances, a unique approach to treating significant diseases with limited side effects. The company targets fibrotic diseases with Primary Sclerosing Cholangitis (PSC) as its first indication. First in class.

GUV contact: Sara Lorentzon